The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2022 | Phase I dose-escalation and expansion study evaluating BI 907828 in patients with solid tumours
Patrick Schöffski, MD, MPH, KU Leuven, Leuven, Belgium, talks on a Phase I dose-escalation and expansion study (NCT03449381) evaluating the safety and efficacy of the MDM2–p53 antagonist BI 907828 in patients with solid tumours. 94 patients were enrolled. The primary endpoint was progression-free survival (PFS) and secondary endpoints included objective response rate (ORR) and the number of patients with grade ≥3 treatment-related adverse events (AEs). Disease control rate was 93% in dedifferentiated liposarcoma (LPS) and 88% in well-differentiated LPS. A confirmed partial response (PR) was achieved in 5 pts and 3 patients had unconfirmed PR. For patients with other solid tumours, 2/4 with MDM2-amplified biliary tract cancer and 1 with MDM2-amplified pancreatic adenocarcinoma had a confirmed PR. Conclusively, BI 907828 demonstrated antitumour activity and a manageable safety profile in patients with advanced solid tumours, including LPS. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.
